In this review glycosidase activated prodrugs that target cancer cells are discussed. Glycosylated prodrugs undergo enzymatic bioconversion, cleaving the prodrug to release the anticancer drug at the desired site of action, hence minimising the toxic side effects associated with many current anticancer drugs. In addition, the presence of the carbohydrate moiety increases the aqueous solubility of the drugs, allowing for a more effective treatment. In the past decade, significant advancements have been made in this field that have led to the development of many novel carbohydrate-based prodrugs – ranging from simple glycoconjugates to complex self-assemblies and materials, which are discussed in detail herein.

中文翻译：

---

用于靶向癌症治疗的糖苷酶激活前药

在这篇综述中，讨论了靶向癌细胞的糖苷酶激活前药。糖基化前药经过酶促生物转化，裂解前药以在所需的作用位点释放抗癌药物，从而最大限度地减少与许多当前抗癌药物相关的毒副作用。此外，碳水化合物部分的存在增加了药物的水溶性，从而实现更有效的治疗。在过去十年中，该领域取得了重大进展，导致许多新型碳水化合物前药的开发——从简单的糖缀合物到复杂的自组装和材料，本文将对此进行详细讨论。